Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

Approximately 9.6% of respondents in a new study self-report having a diagnosed case of 

These findings and others regarding CHE’s prevalence within the US were announced by LEO Pharma Inc. and presented at the 

2025 Fall Clinical Dermatology Conference

. The data resulted from the CHECK (Chronic Hand Eczema epidemiology, Care, and Knowledge) study, presented in 5 posters, during which investigators looked at CHE’s burden and impacts on patients in the US.

“These highly powered survey results provide compelling evidence that chronic hand eczema (or CHE) is a common skin disease in the United States,” Raj Chovatiya, MD, PhD, lead investigator of CHECK and associate professor at Rosalind Franklin University of Medicine and Science Chicago Medical School, said in a statement.

 “By deepening our understanding of its prevalence and identifying who is most likely to have CHE, we can better quantify the broader social and economic burden of this debilitating disease.”

CHE is characterized by hand eczema that persists for longer than 3 months or recurs at least 2 times within a single year. It is among the most prevalent skin diseases impacting one's hands, with roughly 10% of adults worldwide having the condition.

 Those living with CHE can experience pruritus, scaling, erythema, lichenification, vesicles, edema, hyperkeratosis, and fissures on the hands and wrists.

The condition imposes significant psychological and functional impacts on those living with it, with patients’ quality of life often being diminished. Approximately 70% of individuals with severe CHE have difficulty performing everyday tasks, with the disease negatively impacting both career prospects and earning potential among some patients.

Enrollment of participants during the CHECK study involved 10,000 adults in the US aged 18 - 69 years. In Chovatiya and colleagues' research, 9.6% of respondents were reported to have been given a physician diagnosis of this skin disease. This analysis epresents the first comprehensive effort to quantify the prevalence of CHE among those in the general population of the US.

Additionally, higher rates of CHE among younger adults under 40, men, employed individuals, and those residing in urban areas were all identified, emphasizing notable demographic differences in the burden of disease.

Additional CHECK study findings presented in a poster at Fall Clinical detailed disease severity, persistence of symptoms, and patterns related to treatment. Among the 982 subjects included in the study with CHE, 65.1% classified their own disease as being moderate to severe in its severity. More than 80% were shown to have been treated either with topical or systemic medications, yet symptoms such as pain, itch, and sleep disturbance remained common and were frequently rated as moderate in intensity despite therapies implemented.

In another poster, Chovatiya et al had examined CHE's occupational and functional consequences of CHE. In their findings, 27.9% of patients were noted as believing their condition to be connected to their occupation. Additionally, the investigative team found 34.9% attributed their CHE to routine daily activities. As a result of disease symptoms, many of these subjects reported modifying tasks, lowering their own work hours, or even changing professions.

The team also highlighted financial burdens linked with the skin disease in a separate analysis. They found those with moderate to severe CHE had incurred significantly higher monthly out-of-pocket expenses to pay for emollients and other topical options compared with those reporting mild disease (

 < .05). In a national Ipsos survey of 192 healthcare professionals in the US, complementary findings reinforced these patient-reported experiences.

The investigators identified agreement between 90% of clinicians regarding CHE's substantial effects on patients’ ability to work and carry out their activities each day. They also found 51% expressed concerns regarding the limited availability of effective options for moderate to severe disease treatment.

“This collective data highlights that the burden of chronic hand eczema extends far beyond what is visually apparent on the skin, emphasizing the importance of more treatment options to improve disease management," Shannon Schneider, vice president of North America Medical Affairs at LEO Pharma, said in a statement.

LEO Pharma Unveils Data on the U.S. Prevalence of Chronic Hand Eczema at Fall Clinical Dermatology Conference. LEO Pharma, Inc. October 24, 2025. Accessed October 28, 2025. 

https://www.businesswire.com/news/home/20251024915669/en/LEO-Pharma-Unveils-Data-on-the-U.S.-Prevalence-of-Chronic-Hand-Eczema-at-Fall-Clinical-Dermatology-Conference

Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378. Accessed October 28, 2025.

Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158-168. Accessed October 28, 2025.

Articles

Recent data reveal that 9.6% of US adults report a diagnosis of chronic hand eczema (CHE), a prevalent skin condition with significant psychological and functional impacts. The CHECK study, involving 10,000 participants, highlights demographic differences, with higher CHE rates among younger adults, men, and urban residents. Despite treatment, symptoms persist, affecting daily activities and work. Financial burdens are notable, with higher costs for moderate to severe cases. The study underscores the need for more effective treatment options to alleviate the broader social and economic burden of CHE.

In the CHECK study, a cross-sectional survey of over 10,000 participants, the prevalence of chronic hand eczema (CHE) in the US was highlighted.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

US Prevalence of Chronic Hand Eczema Identified in CHECK Study

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Credit: Colorado Permanente Medical Group

Mepolizumab demonstrated clinically meaningful improvements across a range of end-organ systems in new real-world data in patients with eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES).

These findings, from one of the largest real-world analyses to date, were presented at the 

American College of Rheumatology (ACR) Convergence 2025

, held October 24–29 in Chicago, Illinois, by David J. Silverman, MD, Regional Section Chief of Rheumatology for Colorado Permanente Medical Group and Rheumatology Course Director of the Internal Medicine Residency at Saint Joseph Hospital.

“Real-world studies of mepolizumab have shown sustained improvements in clinical outcomes such as remission, and in comorbidities such as asthma in patients with EGPA, as well as reduced numbers of patients experiencing end-organ manifestations of both EGPA and HES,” Silverman and colleagues wrote.

“However, real-world evidence on the changes in clinical manifestations, treatment patterns, and clinical outcomes such as EOD after mepolizumab initiation among patients with HES and EGPA in the US remains limited.”

Silverman and colleagues conducted a retrospective cohort study using administrative claims and EHR data from Optum’s Market Clarity database. The primary outcome was end-organ dysfunction (EOD) proportion & rate and secondary outcome was EOD status change.

The analysis included 1102 patients with EGPA and 784 patients with HES. Among those with EGPA, 375 were mepolizumab users and 727 were chronic standard-of-care (SoC) users. Among those with HES, 198 were mepolizumab users and 586 were chronic SoC users.

The investigators found that mepolizumab was associated with improvements across cardiac, renal, and vascular systems in EGPA and HES. Specifically, mepolizumab significantly improved EOD status compared with chronic SoC in acute kidney failure (

= .026) and chronic kidney disease stage 3 (

= .009) in patients with EGPA, and mitral regurgitation (

Silverman and colleagues noted limitations including small sample sizes and low event rates, as well as a lack of data on prior DMARD or biologic use, which may have influenced observed EOD outcomes. They emphasized that results should be interpreted cautiously, as EOD definitions were based on claims markers of treatment change and healthcare use rather than diagnostic testing.

“These findings suggest treatment with mepolizumab may offer protection against end-organ manifestations, influencing outcomes such as remission, with implications for clinical practice and future research. This goes beyond outcomes demonstrated in RCTs, establishing that mepolizumab has tangible real-world benefits,” Silverman and colleagues wrote.

In other real-world data on organ function presented at ACR Convergence, 

 continued to show efficacy and kidney-protective potential in people with lupus nephritis (LN). Patients in this cohort had more refractory disease, having progressed past prior therapies such as rituximab, belimumab, mycophenolate mofetil, or voclosporin, and began obinutuzumab with lower baseline kidney function (mean eGFR ~70 mL/min/1.73 m²).

In this difficult-to-treat group, 40% (n = 10) of patients achieved complete remission (CR) 32% (n = 8) achieved partial remission (PR), and 28% (n = 7) did not have a response (NR) by 24 months, for around a 70% response rate consistent with pivotal trial outcomes. Proteinuria (UPCR) declined significantly over time (P <.001), while eGFR remained largely stable. Among patients achieving CR or PR, 62% maintained stable or improved kidney function over 2 years.

Importantly, some patients who received only 1 obinutuzumab treatment cycle achieved remission, with the earliest responses at 3 months and others emerging up to 18 months later, underscoring that delayed responders may still benefit from ongoing follow-up. Baseline kidney function strongly predicted response: those with higher initial eGFR were significantly more likely to reach CR (

Silverman D, Barnes T, Odo N, et al. Mepolizumab Reduces End-Organ Manifestations Compared with Standard of Care in Patients with EGPA and HES: A US Real-world Analysis. Presented at: ACR Convergence 2025; October 24-29; Chicago, Illinois. Abstract #LB16

Toz B, Vashistha H, Furie R, et al. Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis. Presented at: ACR Convergence 2025; October 24-29; Chicago, Illinois. Poster #1520

Mepolizumab has shown significant improvements in end-organ systems for patients with eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) in a large real-world study. The study, presented at ACR Convergence 2025, highlighted mepolizumab's efficacy in improving cardiac, renal, and vascular systems compared to standard care. Despite limitations such as small sample sizes, the findings suggest mepolizumab's potential in clinical practice. Additionally, obinutuzumab demonstrated kidney-protective effects in lupus nephritis, with a notable response rate and stable kidney function over two years.

Mepolizumab shows significant real-world benefits in reducing end-organ dysfunction.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Mepolizumab Demonstrates Benefit for End Organ Dysfunction in EGPA and HES

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

Diabetes Dialogue: Oral Semaglutide and SELECT at DTM 2025

In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, meet in person at the Diabetes Technology Meeting (DTM) in San Francisco to discuss the latest clinical and regulatory advances surrounding semaglutide.

00:02:02 The SOUL trial and Rybelsus's cardiovascular indication

00:08:29 Can GLP-1s be cardiovascular treatments?

 approval of oral semaglutide (Rybelsus) for reducing cardiovascular risk in adults with 

. This marks a major milestone as the first and only oral GLP-1 receptor agonist to receive a cardiovascular risk–reduction indication. Isaacs and Bellini emphasize how this approval validates the cardiovascular benefits previously observed with injectable semaglutide, offering clinicians a new oral option for patients who are resistant to injections while maintaining evidence-based protection against major cardiovascular events.

They highlight that this new indication builds upon data from the SOUL trial, which confirmed the cardiovascular benefit of oral semaglutide, and discuss how this approval will expand adoption among patients seeking non-injectable therapies. The hosts underscore practical considerations for its use - namely, that oral semaglutide must be taken on an empty stomach with up to four ounces of water and separated from food and other medications by at least 30 minutes to ensure reliable absorption. They also preview upcoming developments, including next-generation formulations expected to offer higher potency (25 mg and 50 mg) and enhanced convenience for patients, potentially broadening access and adherence.

Transitioning to recent research, Isaacs and Bellini analyze a pre-specified subanalysis from the SELECT trial, published in 

, which explored whether semaglutide’s cardiovascular benefits are mediated by weight loss or by intrinsic molecular mechanisms. Interestingly, the data revealed little correlation between weight loss and reductions in cardiovascular events, suggesting that semaglutide may exert direct anti-inflammatory or disease-modifying effects independent of its impact on body weight or glycemia. Drawing parallels to statins, the hosts note that GLP-1 receptor agonists may provide cardiovascular protection beyond their metabolic effects.

They further discuss implications for the broader incretin class - GLP-1, GIP, and emerging dual and triple agonists - raising the question of whether cardiovascular benefits are class-wide or molecule-specific. The conversation concludes with reflections on the off-label but growing use of GLP-1 therapy in type 1 diabetes, calls for further cardiovascular outcomes research in this population, and anticipation for more insights from DTM sessions exploring these evolving therapeutic frontiers.

Podcasts

This episode covers the recent approval of oral semaglutide for T2D and a pre-specified subanalysis of the SELECT trial.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Walker Redd, MD, is a gastroenterologist and assistant professor of medicine at UNC School of Medicine.

Closing the Diagnostic Gap in Eosinophilic Esophagitis, With Walker Redd, MD

Diagnostic delays in eosinophilic esophagitis (EoE) remain a major challenge, often spanning years from symptom onset to confirmed diagnosis. While subtle symptoms, limited disease awareness, and brief primary care visits contribute, one of the most actionable barriers occurs during endoscopy for esophageal food impaction (EFI), a common first presentation of undiagnosed EoE.

American College of Gastroenterology (ACG)’s 2025 Annual Scientific Meeting

, Walker Redd, MD, a gastroenterologist and assistant professor of medicine at UNC School of Medicine, presented real-world data examining the management of EFI cases during and after emergency department visits in the community setting, with study findings shedding light on infrequent esophageal biopsies at the index endoscopy and subsequent missed opportunities for EoE diagnosis.

“One of the things we've been interested in, based on some smaller, single center studies, is the frequency with which biopsies are performed,” Redd explained to 

. “When a patient gets food stuck in their esophagus, it's often a way that EoE presents–patients who have not been diagnosed often come in and have food stuck… but there's been some hesitancy, or just lack of knowledge that biopsies need to be performed after the food bolus is removed from the esophagus.”

Current EoE guidelines from the ACG recommend diagnosing EoE based on the presence of symptoms of esophageal dysfunction and ≥ 15 eosinophils per high-power field on esophageal biopsy, after evaluating for non-EoE disorders that cause or potentially contribute to esophageal eosinophilia. However, despite biopsy being required to make a diagnosis, a growing body of research suggests it is not being routinely done in clinical practice.

Seeking to provide more robust real-world data on biopsy practices, Redd and colleagues conducted a retrospective cohort study using deidentified electronic medical records from a real-world data repository from 58 gastroenterology practices across 6 US states from January 2018 to June 2024. For inclusion, patients were required to have ≥1 ED visit with an associated ICD-10 diagnosis code for EFI, ≥12 months of data after index ED visit, and age ≥18 years at index.

A total of 2566 patients with EFI-related ED visits were identified. Among the cohort, 2534 (98.8%) patients underwent EGD at the time of index ED visit, the mean age at presentation was 59 years, and 1231 (48.6%) were female. At the index EGD, investigators noted 108 (4.3%) patients underwent a dilation, 739 (29.2%) had a code for biopsies, and of these, 191 (25.8%) received an EoE diagnosis.

Of the 1795 (70.8%) patients who did not have biopsies collected during the index EGD, 837 (46.6%) were lost to follow up and 206 (11.5%) had an outpatient follow up EGD performed within 1 year after the EFI-related ED visit.

“These data basically demonstrate, in the largest data set that I think has been assessed so far, that the biopsy rate at time of food impaction remains unacceptably low,” Redd said. “While that is unfortunate on one hand, that the biopsy rate and the rate of follow up remain too low, it's actually a tremendous opportunity for quality improvement.”

Looking ahead, he points to the need for continued emphasis on taking esophageal biopsies at time of food impaction as well as a greater focus on ensuring biopsy results make it to both the physician and the patient so that shared decision-making conversations about therapy can ensue.

Editors’ note: Redd reports relevant disclosures with Sanofi.

Redd WD, Dellon ES, Bekal PK, et al. Real-World Study of Biopsy Practices During Food Impactions in the Emergency Department: Multi-State GI Practice. Presented at the American College of Gastroenterology (ACG)’s 2025 Annual Scientific Meeting. Phoenix, Arizona. October 27-29, 2025.

Dellon ES, Muir AB, Katzka DA, et al. ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis. 

Videos

Redd reviews real-world data highlighting low rates of biopsies performed among patients with esophageal food impaction-related emergency department visits.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Switching to an IL-17 inhibitor (IL-17i) after failure of a first TNF inhibitor (TNFi) was not superior to cycling to a second TNFi in people with axial 

These findings, from the prospective, randomized, multicenter, superiority open-label phase 4 ROC-SpA (Rotation Or Change of biotherapy after first TNFi treatment failure in AxSpA patients) study were presented at the 

, held October 24–29 in Chicago, Illinois, by Hubert Marotte, MD, PhD, University of Saint-Etienne, France.

“AxSpA is initially treated with non-steroidal anti-inflammatory drugs. In case of inadequate response, ACR/EULAR recommend biological disease modifying antirheumatic drugs (bDMARDs). Until 2015, TNFi were the only available option. Since then, IL-17i have also demonstrated efficacy on axSpA. The 2022 ASAS-EULAR guidance proposes switching an alternative bDMARD after TNF inhibitors failure without mandating a change of mechanism,” Marotte and colleagues wrote.

The study enrolled 300 patients with AxSpA who had an inadequate response after 3 months of first-line TNFi therapy and were maintained on stable doses of csDMARDs, corticosteroids, or NSAIDs for at least 1 month, across 31 centers in France. Participants were randomized to receive either an IL-17i (n = 158) or a second TNFi (n = 142). The primary endpoint was the proportion of patients achieving an ASAS40 response at week 24, with secondary outcomes including ASAS40 responses at weeks 12 and 52, as well as ASAS20, partial remission rates, and ASDAS major improvement at weeks 12, 24, and 52.

Marotte and colleagues found that the primary endpoint of IL-17i superiority was not met, with a similar ASAS40 clinical response between IL-17i (15.2%) and TNFi (14.5%) at week 24 Furthermore, there were no statistically significant differences observed between groups for other secondary endpoints.

The investigators did find trends that were in favor of IL-17i, according to the cause of failure of the first TNFi, and other subgroups. Patients who had first TNFi failure due to primary nonresponse had a trend in favor of IL-17i (odds ratio [OR] of nonresponse, 0.69 (95% CI, 0.27-1.76) while on the other hand, failures due to adverse events favored another TNFi (OR of IL-17i nonresponse, 1.49; 95% CI, 0.42-5.32). Trends favoring IL-17i were also seen in case of skin psoriasis, HLA B27 negative status, or low CRP (< 5mg/L). At week 24, the mean ASDAS decreased to 2.5 (standard deviation, 1.0) in both groups, with no difference between groups.

“In this randomized trial of AxSpA patients with inadequate response to a first TNFi, switching to an IL-17i was not superior to cycling to a second TNFi for the primary endpoint. These findings directly inform treatment sequencing after TNFi failure and provide valuable evidence to guide individualized, shared decision-making in AxSpA management,” Marotte and colleagues concluded.

Another comparative study post TNFi, the AgAIN study (NCT04632927), whose findings were presented at the ACR Convergence looked at comparing secukinumab (Cosentyx; Novartis) with ustekinumab (Stelara; Janssen) in patients with psoriatic arthritis (PsA). At week 28, 57.1% of patients treated with secukinumab achieved a HAQ-DI response (≥0.35-point improvement) compared with 27.0% in the ustekinumab group (OR 3.647; 95% CI, 1.601–8.311; P = .002), nearly doubling response rates with IL-17 inhibition over IL12/IL23 inhibition, with secondary end points further supporting the switch to IL-17i.

 Professor and Head of Translational Rheumatology, Immunology, and Inflammation Medicine and Head of the Inflammation Clinic at Goethe-University Frankfurt, who presented the findings during the meeting.

“The question was whether I should go first to ustekinumab prior to go for a p19 IL-23 inhibitor like guselkumab and risankizumab or an IL-17. And this question was not answered yet. And we helped people and doctors to understand the value of secukinumab compared to ustekinumab in these individual patients,” Behrens said.

Dalix E, Goupille P, Wendling D, et al. Rotation or Change of Biologic After TNF blocker treatment failure for axial Spondyloarthritis. Presented at: ACR Convergence 2025; October 24-29; Chicago, Illinois. Poster #LB09.

Behrens F, Sternad P, Krueger K, et al. AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains. Presented at: ACR Convergence 2025; October 24-29; Chicago, Illinois. Poster #LB06.

Switching to an IL-17 inhibitor after the failure of a first TNF inhibitor in axial spondyloarthritis patients did not show superiority over cycling to a second TNF inhibitor. The study involved 300 patients and assessed ASAS40 response at week 24 as the primary endpoint. Although no significant differences were found between the two groups, trends favored IL-17 inhibitors in specific subgroups. Another study, AgAIN, demonstrated better efficacy of secukinumab over ustekinumab in psoriatic arthritis patients, highlighting the potential benefits of IL-17 inhibition.

Switching to an IL-17 inhibitor after TNF inhibitor failure showed no superior benefits for axial spondyloarthritis.

Psoriatic Arthritis

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.

Spondyloarthritis

The HCPLive spondyloarthritis page is a resource for medical news and expert insights on spondylitis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for autoimmune disease, and more.

ROC-SpA: IL-17i Not Superior to Cycling TNFi Post-Failure in AxSpA

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

GLP-1 RA use was linked to a significant survival benefit and reduced risk of iron deficiency anemia in patients with celiac disease.

Hematology

Anemia

GLP-1 RAs Reduce Anemia Risk in Patients with Celiac Disease

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Artificial Intelligence-Assisted Model Can Automate Diagnosis of Glomerular Nephritis. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Improved Glomerular Nephritis Diagnosis With Artificial Intelligence-Assisted Model 

Evan Dellon, MD, MPH, is a professor in the division of gastroenterology and hepatology and director of the Center for Esophageal Diseases and Swallowing at UNC School of Medicine.

Dellon reviews data from a post-hoc analysis of dysphagia and odynophagia in LIBERTY EoE TREET and a pooled analysis of endoscopic improvement in 2 trials.

Solidifying Dupilumab’s Role in Eosinophilic Esophagitis Care, With Evan Dellon, MD, MPH

Lee Schwamm, MD, discusses how AI-powered documentation tools are reshaping notetaking, patient engagement, and medical training.

Internal Medicine

Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.

AI Scribes Help Reduce Burnout, With Lee Schwamm, MD

Basile Njei, MD, PhD, MPH, is an assistant professor at Yale School of Medicine.

Njei explains the utility of Fibro-GPT for detecting advanced fibrosis and predicting hepatic decompensation in MASLD.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Using AI to Improve Risk Stratification, Disease Management in MASLD, With Basile Njei, MD, PhD, MPH

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

In a post-hoc analysis of the KINGFISHER trial, brolucizumab resulted in improved BCVA and anatomical outcomes regardless of prior anti-VEGF treatment.

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Diabetic Macular Edema

The HCPLive diabetic macular edema page is a comprehensive resource for clinical news and insights on DME. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the leading cause of blindness, and more.

Brolucizumab Outperforms Aflibercept in DME Regardless of Prior Treatment

The investigative GLP-1/GCG dual receptor agonist led to a higher proportion of participants achieving HbA1c and body weight improvements from baseline.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Mazdutide Demonstrates Superiority to Semaglutide in Type 2 Diabetes and Obesity

Donna Culton, MD, PhD, is professor of dermatology at the University of North Carolina at Chapel Hill

This Fall Clinical interview features a series of highlights from Culton’s portion of the session ‘Bullous Pemphigoid: The Time to Treat is Now.’

Treatment and Diagnosis Strategies for Bullous Pemphigoid, With Donna Culton, MD, PhD

Michelle Rodrigues, MBBS, is a dermatologist in Australia.

In this episode, Michelle Rodrigues, MBBS, joins Skin of Color Savvy from EADV 2025 to discuss facial hyperpigmentation in richly pigmented skin.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Skin of Color Savvy: Insights on Hyperpigmentation from EADV, With Michelle Rodrigues, MBBS

Panelists discuss how nonsteroidal PDE-4 and JAK inhibitors offer effective, targeted relief while addressing caregiver concerns about safety and chronic use.

Video Series

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Latest News

US Prevalence of Chronic Hand Eczema Identified in CHECK Study

Mepolizumab Demonstrates Benefit for End Organ Dysfunction in EGPA and HES

Diabetes Dialogue: Oral Semaglutide and SELECT at DTM 2025

Closing the Diagnostic Gap in Eosinophilic Esophagitis, With Walker Redd, MD

ROC-SpA: IL-17i Not Superior to Cycling TNFi Post-Failure in AxSpA